Deborah J Marsh
Overview
Explore the profile of Deborah J Marsh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
1821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Xie T, Dickson K, Yee C, Ma Y, Ford C, Bowden N, et al.
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230543
The advent of molecular targeted therapies has made a significant impact on survival of women with ovarian cancer who have defects in homologous recombination repair (HRR). High-grade serous ovarian cancer...
12.
Liu D, Kaufmann G, Breitmeyer J, Dickson K, Marsh D, Ford C
Pharmaceutics
. 2022 Apr;
14(4).
PMID: 35456672
The non-canonical Wnt signalling receptor ROR1 is aberrantly expressed in numerous cancers, including ovarian and endometrial cancer. We previously reported that silencing ROR1 could inhibit the proliferation and metastatic potential...
13.
Yee C, Dickson K, Muntasir M, Ma Y, Marsh D
Front Bioeng Biotechnol
. 2022 Feb;
10:836984.
PMID: 35223797
Ovarian cancer has the highest mortality of all of the gynecological malignancies. There are several distinct histotypes of this malignancy characterized by specific molecular events and clinical behavior. These histotypes...
14.
Joshi N, Liu D, Dickson K, Marsh D, Ford C, Stenzel M
J Mater Chem B
. 2021 Oct;
9(44):9123-9135.
PMID: 34676865
High-grade serous ovarian cancer (HGSOC) is the most lethal gynaecological malignancy. Most patients are diagnosed at late stages when the tumour has metastasised throughout the peritoneal cavity. The Wnt receptor...
15.
Dickson K, Xie T, Evenhuis C, Ma Y, Marsh D
Int J Mol Sci
. 2021 Aug;
22(16).
PMID: 34445211
Several poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors are now in clinical use for tumours with defects in BReast CAncer genes or that result in deficient homologous recombination repair (HRR). Use...
16.
Travis G, Haddadi N, Simpson A, Marsh D, McGowan E, Nassif N
Methods Mol Biol
. 2021 Jun;
2324:165-185.
PMID: 34165715
PTENP1 is a processed pseudogene of the tumour suppressor phosphatase and tensin homolog deleted on chromosome 10 (PTEN). It functions posttranscriptionally to regulate PTEN by acting as a sponge for...
17.
Bolitho C, Moscova M, Baxter R, Marsh D
Mol Cell Endocrinol
. 2021 Jun;
533:111338.
PMID: 34062166
The epidermal growth factor receptor (EGFR) is overexpressed in many types of cancer, including epithelial ovarian cancer (EOC), and its expression has been found to correlate with advanced stage and...
18.
Histone Monoubiquitination in Chromatin Remodelling: Focus on the Histone H2B Interactome and Cancer
Marsh D, Ma Y, Dickson K
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33233707
Chromatin remodelling is a major mechanism by which cells control fundamental processes including gene expression, the DNA damage response (DDR) and ensuring the genomic plasticity required by stem cells to...
19.
Cole A, Dickson K, Liddle C, Stirzaker C, Shah J, Clifton-Bligh R, et al.
Cell Mol Life Sci
. 2020 May;
78(3):1011-1027.
PMID: 32458023
Modification of the cancer-associated chromatin landscape in response to therapeutic DNA damage influences gene expression and contributes to cell fate. The central histone mark H2Bub1 results from addition of a...
20.
Haddadi N, Travis G, Nassif N, Simpson A, Marsh D
Cold Spring Harb Perspect Med
. 2019 Oct;
10(5).
PMID: 31615872
Germline alterations of the tumor suppressor PTEN have been extensively characterized in patients with PTEN hamartoma tumor syndromes, encompassing subsets of Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, Proteus and Proteus-like syndromes, as...